Iqbal Sabah, Zhuang Eric, Raj Moses, Bahary Nathan, Monga Dulabh K
Mercy Catholic Medical Center, Darby, PA, United States.
Department of Hematology and Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States.
Front Oncol. 2024 May 16;14:1393317. doi: 10.3389/fonc.2024.1393317. eCollection 2024.
The incidence of gastroenteropancreatic neuroendocrine tumors has been rising and these tumors are usually only diagnosed at a metastatic stage. Present first line treatments include somatostatin analogs, targeted therapies and peptide receptor radionuclide therapy. The Lutetium-177 [Lu] based radiotracer [Lu]Lu-DOTATATE has only been approved as first-line treatment of metastatic midgut NETs however its efficacy as a third line or above treatment in patients with non ileal primaries has not been tested. In our study, we identified 25 patients with histologically confirmed well-differentiated metastatic neuroendocrine tumors and administered [Lu]Lu-DOTATATE as a second line, third line and fourth line treatment. Our study demonstrated a notable response in patients with non-ileal primaries and heavily pretreated disease, warranting further studies for additional cycles of treatment.
胃肠胰神经内分泌肿瘤的发病率一直在上升，这些肿瘤通常仅在转移阶段才被诊断出来。目前的一线治疗方法包括生长抑素类似物、靶向治疗和肽受体放射性核素治疗。基于镥-177[Lu]的放射性示踪剂[Lu]Lu-DOTATATE仅被批准作为转移性中肠神经内分泌肿瘤的一线治疗药物，然而，其作为非回肠原发性患者三线及以上治疗的疗效尚未得到检验。在我们的研究中，我们确定了25例经组织学证实为高分化转移性神经内分泌肿瘤的患者，并将[Lu]Lu-DOTATATE作为二线、三线和四线治疗药物进行给药。我们的研究表明，非回肠原发性且经过大量预处理的疾病患者有显著反应，有必要对额外的治疗周期进行进一步研究。
